PONIARD PHARMAECUTICALS INC. PARD (NASDAQ) $ 2.90 Change: 0 0% | Volume: 18,619
Sponsored by Click here!
Headlines on PARD
Alert me Subscribe

Erbitux data could help doctors' treatment decisions

(NEW YORK)Data presented over the weekend on Bristol-Myers Squibb/ImClone Systems Inc.'s colorectal cancer treatment Erbitux could provide doctors a better way of treating the disease.READ MORE
Jun 02, 2008 3:53PM
Keywords: IMCL, PARD, BMY, DNA

Market Spotlight: Cancer drug conference

(NEW YORK)With cancer drugs making up the bulk of sales for many biotech companies, Wall Street is gearing up for one of the year's most anticipated medical conferences, the American Soc...READ MORE
May 28, 2008 5:07PM
Keywords: CELG, DNA, MLNM, IMCL, BMY, MRK, SNY, PARD, ARIA

Sector Wrap: Celgene, Genentech in ASCO spotlight

(NEW YORK)Analysts said Celgene Corp. and Genentech Inc. are their top picks heading into the 44th annual American Society of Clinical Oncology meeting, or ASCO, taking place May 30 to June ...READ MORE
May 16, 2008 4:04PM
Keywords: CELG, DNA, IMCL, AMGN, ARIA, CGRB, EXEL, GENZ, IMGN, OSIP, PARD


Data Provided By Barchart.com
advertisement

Top Competitors

PFIZER INC -26.60 16.43
JOHNSON AND JOH -14.40 58.58
BRISTOL MYERS S -21.50 20.70
SCHERING PLOUGH -38.30 16.81
MERCK CO INC -53.90 26.72